Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01059864 · ClinicalTrials.gov registry record · Phase 2
Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT01059864 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 111 participants.
The verdict
NCT01059864, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the cholesterol lowering agent, atorvastatin, and half a matching placebo. This study will first measure the effects of CP-690,550 on cholesterol levels and then the effects of adding atorvastatin on those levels.
Interventions
- DRUG Atorvastatin
- DRUG CP-690,550
- DRUG Atorvastatin Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01059864
The ClinicalTrials.gov registry entry for NCT01059864 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atorvastatin is the first listed.
NCT01059864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01059864 about?
NCT01059864 is a clinical study titled "Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550". All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the cholesterol lowering agent, atorvastatin, and half a matching placebo. This study will first measure the effects of CP-690,55...
What is the current status of trial NCT01059864?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2010-02. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01059864?
The interventions under investigation include: Atorvastatin (DRUG), CP-690,550 (DRUG), Atorvastatin Placebo (DRUG).
Who is sponsoring clinical trial NCT01059864?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.